| RS2541492816 |
FREM2
|
Health Risk |
Pathogenic |
— |
| RS2541493503 |
ANO4
|
Health Risk |
Pathogenic |
Developmental and epileptic encephalopathy, Developmental and epileptic encephalopathy |
| RS2541494253 |
FREM2
|
Health Risk |
Likely pathogenic |
— |
| RS2541494324 |
FREM2
|
Health Risk |
Pathogenic |
— |
| RS2541495847 |
FREM2
|
Health Risk |
Pathogenic/Likely pathogenic |
Isolated cryptophthalmia, Fraser syndrome 2 |
| RS2541497232 |
FREM2
|
Health Risk |
Likely pathogenic |
— |
| RS2541497277 |
FREM2
|
Health Risk |
Likely pathogenic |
Fraser syndrome 2, Fraser syndrome 2 |
| RS2541498472 |
RNASEH2B
|
Health Risk |
Likely pathogenic |
Aicardi-Goutieres syndrome 2, Aicardi-Goutieres syndrome 2 |
| RS2541504813 |
FREM2
|
Health Risk |
Likely pathogenic |
Fraser syndrome 1, Fraser syndrome 1 |
| RS2541507210 |
FREM2
|
Health Risk |
Likely pathogenic |
FREM2-related disorder, FREM2-related disorder |
| RS2541507235 |
FREM2
|
Health Risk |
Likely pathogenic |
Fraser syndrome 2, Fraser syndrome 2 |
| RS2541507566 |
FREM2
|
Health Risk |
Likely pathogenic |
— |
| RS2541510478 |
ABCC9
|
Health Risk |
Likely pathogenic |
Dilated cardiomyopathy 1O, Dilated cardiomyopathy 1O |
| RS2541520331 |
ADAMTS15
|
Health Risk |
Pathogenic |
Arthrogryposis, distal |
| RS2541521563 |
CEP164
|
Health Risk |
Likely pathogenic |
Nephronophthisis 15, Nephronophthisis 15 |
| RS2541531608 |
RNASEH2B
|
Health Risk |
Pathogenic |
Aicardi-Goutieres syndrome 2, Aicardi-Goutieres syndrome 2 |
| RS2541533331 |
ANO4
|
Health Risk |
Pathogenic |
Developmental and epileptic encephalopathy, Developmental and epileptic encephalopathy |
| RS2541541908 |
SPTAN1
|
Health Risk |
Likely pathogenic |
Early-infantile DEE, Early-infantile DEE |
| RS2541543792 |
RNASEH2B
|
Health Risk |
Likely pathogenic |
Aicardi-Goutieres syndrome 2, Aicardi-Goutieres syndrome 2 |
| RS2541545118 |
ADAMTS15
|
Health Risk |
Likely pathogenic |
Arthrogryposis, distal |
| RS2541567891 |
CEP164
|
Health Risk |
Pathogenic |
Nephronophthisis 15, Nephronophthisis 15 |
| RS2541569380 |
CEP164
|
Health Risk |
Pathogenic |
Nephronophthisis 15, Nephronophthisis 15 |
| RS2541594859 |
PTPRQ
|
Health Risk |
Pathogenic |
Autosomal recessive nonsyndromic hearing loss 84A, Autosomal recessive nonsyndromic hearing loss 84A |
| RS2541600597 |
PTPRQ
|
Health Risk |
Likely pathogenic |
Autosomal recessive nonsyndromic hearing loss 84A, Autosomal recessive nonsyndromic hearing loss 84A |
| RS2541615817 |
CEP164
|
Health Risk |
Pathogenic |
Nephronophthisis 15, Nephronophthisis 15 |
| RS2541617396 |
EHMT1
|
Health Risk |
Pathogenic |
Kleefstra syndrome 1, Kleefstra syndrome |
| RS2541617604 |
EHMT1
|
Health Risk |
Pathogenic |
Kleefstra syndrome 1, Kleefstra syndrome 1 |
| RS2541620694 |
RNASEH2B
|
Health Risk |
Pathogenic |
Aicardi-Goutieres syndrome 2, Aicardi-Goutieres syndrome 2 |
| RS2541627484 |
ABCC9
|
Health Risk |
Likely pathogenic |
Dilated cardiomyopathy 1O, Dilated cardiomyopathy 1O |
| RS2541632016 |
KPNA3
|
Health Risk |
Pathogenic |
Spastic paraplegia 88, autosomal dominant |
| RS2541632753 |
KPNA3
|
Health Risk |
Pathogenic |
Spastic paraplegia 88, autosomal dominant |
| RS2541635988 |
KPNA3
|
Health Risk |
Pathogenic |
Spastic paraplegia 88, autosomal dominant |
| RS2541636017 |
KPNA3
|
Health Risk |
Pathogenic |
Spastic paraplegia 88, autosomal dominant |
| RS2541636062 |
KPNA3
|
Health Risk |
Likely pathogenic |
Spastic paraplegia 88, autosomal dominant |
| RS2541647390 |
KPNA3
|
Health Risk |
Likely pathogenic |
— |
| RS2541667090 |
ABCC9
|
Health Risk |
Pathogenic |
Dilated cardiomyopathy 1O, Dilated cardiomyopathy 1O |
| RS2541667683 |
ABCC9
|
Health Risk |
Pathogenic |
Dilated cardiomyopathy 1O, Dilated cardiomyopathy 1O |
| RS2541668124 |
ABCC9
|
Health Risk |
Pathogenic |
Dilated cardiomyopathy 1O, Dilated cardiomyopathy 1O |
| RS2541668805 |
SUCLA2
|
Health Risk |
Likely pathogenic |
Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria |
| RS2541673501 |
SUCLA2
|
Health Risk |
Pathogenic |
Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria |
| RS2541675859 |
EIF2B1
|
Health Risk |
Pathogenic |
— |
| RS2541676016 |
EIF2B1
|
Health Risk |
Likely pathogenic |
— |
| RS2541676186 |
EIF2B1
|
Health Risk |
Likely pathogenic |
— |
| RS2541677216 |
ABCC9
|
Health Risk |
Pathogenic |
Dilated cardiomyopathy 1O, Dilated cardiomyopathy 1O |
| RS2541678147 |
CEP83
|
Health Risk |
Pathogenic |
Nephronophthisis 18, Nephronophthisis 18 |
| RS2541679076 |
EIF2B1
|
Health Risk |
Pathogenic |
— |
| RS2541679267 |
EIF2B1
|
Health Risk |
Likely pathogenic |
— |
| RS2541682153 |
EIF2B1
|
Health Risk |
Likely pathogenic |
— |
| RS2541687655 |
CPAP
|
Health Risk |
Likely pathogenic |
CENPJ-related disorder, CENPJ-related disorder |
| RS2541687729 |
CPAP
|
Health Risk |
Pathogenic |
— |
| RS2541694352 |
CPAP
|
Health Risk |
Pathogenic |
— |
| RS2541695491 |
FANCC
|
Health Risk |
Likely pathogenic |
Fanconi anemia complementation group C, Fanconi anemia complementation group C |
| RS2541698973 |
FANCC
|
Health Risk |
Pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2541701286 |
FANCC
|
Health Risk |
Likely pathogenic |
Fanconi anemia complementation group C, Fanconi anemia complementation group C |
| RS2541701808 |
FANCC
|
Health Risk |
Likely pathogenic |
Fanconi anemia complementation group C, Fanconi anemia complementation group C |
| RS2541724555 |
ACBD5
|
Health Risk |
Pathogenic |
— |
| RS2541735680 |
ABCC9
|
Health Risk |
Pathogenic |
Dilated cardiomyopathy 1O, Dilated cardiomyopathy 1O |
| RS2541736804 |
ABCC9
|
Health Risk |
Likely pathogenic |
Cardiovascular phenotype, Cardiovascular phenotype |
| RS2541745804 |
TCTN2
|
Health Risk |
Likely pathogenic |
Joubert syndrome, Meckel-Gruber syndrome |
| RS2541746245 |
TCTN2
|
Health Risk |
Pathogenic |
— |
| RS2541746254 |
TCTN2
|
Health Risk |
Likely pathogenic |
Meckel-Gruber syndrome, Joubert syndrome |
| RS2541751074 |
TCTN2
|
Health Risk |
Likely pathogenic |
Joubert syndrome, Meckel-Gruber syndrome |
| RS2541771087 |
CEP164
|
Health Risk |
Pathogenic |
Nephronophthisis 15, Nephronophthisis 15 |
| RS2541775874 |
TCTN2
|
Health Risk |
Likely pathogenic |
Joubert syndrome, Meckel-Gruber syndrome |
| RS2541781408 |
EHMT1
|
Health Risk |
Likely pathogenic |
Kleefstra syndrome 1, Kleefstra syndrome 1 |
| RS2541792114 |
TCTN2
|
Health Risk |
Pathogenic |
Joubert syndrome, Meckel-Gruber syndrome |
| RS2541798281 |
TCTN2
|
Health Risk |
Pathogenic/Likely pathogenic |
Joubert syndrome and related disorders, Meckel syndrome |
| RS2541806985 |
TCTN2
|
Health Risk |
Pathogenic |
Joubert syndrome, Meckel-Gruber syndrome |
| RS2541810812 |
TCTN2
|
Health Risk |
Likely pathogenic |
Joubert syndrome 24, Joubert syndrome 24 |
| RS2541822774 |
ATP6V0A2
|
Health Risk |
Likely pathogenic |
Cutis laxa with osteodystrophy, Cutis laxa with osteodystrophy |
| RS2541827197 |
ABCC9
|
Health Risk |
Conflicting classifications of pathogenicity |
Cardiovascular phenotype, Dilated cardiomyopathy 1O |
| RS2541833313 |
POLE
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2541837678 |
POLE
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2541841120 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2541846029 |
ATP6V0A2
|
Health Risk |
Pathogenic |
ALG9 congenital disorder of glycosylation, ALG9 congenital disorder of glycosylation |
| RS2541847990 |
ATP6V0A2
|
Health Risk |
Conflicting classifications of pathogenicity |
ALG9 congenital disorder of glycosylation, ALG9 congenital disorder of glycosylation |
| RS2541854318 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2541855859 |
POLE
|
Health Risk |
Conflicting classifications of pathogenicity |
— |
| RS2541856342 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2541856897 |
WBP4
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurodevelopmental disorder, Neurodevelopmental disorder with hypotonia |
| RS2541859093 |
WBP4
|
Health Risk |
Likely pathogenic |
Neurodevelopmental disorder, Neurodevelopmental disorder |
| RS2541859702 |
POLE
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2541859762 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2541860346 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2541863349 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2541865278 |
ATP6V0A2
|
Health Risk |
Pathogenic |
ALG9 congenital disorder of glycosylation, ALG9 congenital disorder of glycosylation |
| RS2541868865 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2541871623 |
ATP6V0A2
|
Health Risk |
Pathogenic |
ALG9 congenital disorder of glycosylation, ALG9 congenital disorder of glycosylation |
| RS2541872719 |
ATP6V0A2
|
Health Risk |
Likely pathogenic |
ALG9 congenital disorder of glycosylation, ALG9 congenital disorder of glycosylation |
| RS2541877986 |
ABCC9
|
Health Risk |
Pathogenic |
Dilated cardiomyopathy 1O, Dilated cardiomyopathy 1O |
| RS2541878110 |
EHMT1
|
Health Risk |
Likely pathogenic |
Kleefstra syndrome 1, Kleefstra syndrome 1 |
| RS2541878282 |
ATP6V0A2
|
Health Risk |
Likely pathogenic |
Cutis laxa, Cutis laxa |
| RS2541879513 |
EHMT1
|
Health Risk |
Likely pathogenic |
— |
| RS2541880452 |
POLE
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2541880994 |
POLE
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2541881067 |
POLE
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2541881074 |
POLE
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2541881193 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2541883373 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2541883589 |
POLE
|
Health Risk |
Pathogenic |
— |